Stockscreener 앱 받기
4.96
6.59%
-0.35
시장 영업 전:
4.93
-0.03
-0.60%
전일 마감가:
$5.31
열려 있는:
$5.29
하루 거래량:
2.69M
시가총액:
$3.48B
수익:
$956.00K
순이익/손실:
$-614.93M
주가수익비율:
-2.9504
EPS:
-1.6811
순현금흐름:
$-76.89M
1주 성능:
+5.53%
1개월 성능:
+25.89%
6개월 성능:
+171.78%
1년 성능:
+155.67%
1일 변동 폭
$4.94
$5.39
52주 변동 폭
$1.50
$5.39
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
44 12 3544 3939
주소
136a Eastern Avenue, Milton Park, Abingdon
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Wall Street Breakfast: The Week Ahead
Seeking Alpha
Why Summit Therapeutics Stock Crushed the Market This Week
The Motley Fool
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment
Benzinga
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
Benzinga
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Summit Therapeutics Inc (SMMT) 재무 분석
Summit Therapeutics Inc (SMMT) 매출 2024
SMMT은 2022-09-30 종료 분기에 대해 매출(지난 12개월)이 956.00K 달러로 보고했으며, 전년대비 -45.15% 감소했습니다.
Summit Therapeutics Inc (SMMT) 순이익 2024
SMMT은 2023-12-31 종료 분기에 대해 순이익(지난 12개월)이 -614.93M 달러로 보고했으며, 전년대비 -680.54% 감소했습니다.
Summit Therapeutics Inc (SMMT) 현금흐름 2024
2023-12-31 종료 분기에 SMMT은 현금흐름(지난 12개월)으로 -76.89M 달러를 기록했으며, 전년 대비 -82.17% 감소했습니다.
Summit Therapeutics Inc (SMMT) 주당 순이익 2024
SMMT이 보고한 2023-12-31 종료 분기의 주당 순이익(지난 12개월)은 -1.49달러이며, 전년 대비 -263.41% 감소했습니다.
Summit Therapeutics Inc 주식 (SMMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Chief Executive Officer |
Mar 27 '24 |
Buy |
3.72 |
54,321 |
201,874 |
24,923,800 |
| Zanganeh Mahkam | Chief Executive Officer |
Mar 27 '24 |
Buy |
3.72 |
26,000 |
96,720 |
520,814 |
| Dhingra Ankur | Chief Financial Officer |
Mar 26 '24 |
Buy |
3.75 |
100,000 |
375,000 |
354,958 |
| Zanganeh Mahkam | Chief Executive Officer |
Mar 26 '24 |
Buy |
3.75 |
30,000 |
112,500 |
30,000 |
| Dhingra Ankur | Chief Financial Officer |
Dec 13 '23 |
Buy |
2.17 |
20,400 |
44,254 |
254,958 |
| Zanganeh Mahkam | Chief Executive Officer |
Dec 12 '23 |
Buy |
2.07 |
5,000 |
10,350 |
494,814 |
| Soni Manmeet Singh | Chief Operating Officer |
Oct 13 '23 |
Buy |
1.68 |
2,976,190 |
4,999,999 |
2,976,190 |
0.91%
2.42%
자본화:
|
볼륨(24시간):